BTOG 2017 | Early clinical trials of immunotherapy treatment combinations
Juergen Wolf
Prof Jürgen Wolf, MD, University Hospital of Cologne, Cologne, Germany, talks about early clinical trials investigating combinations of immune checkpoint inhibitors with other immune-stimulatory molecules and other modulators of interactions in the immune system. Other areas of investigation examine combinations of immunotherapy with chemotherapy, or with radiotherapy. Prof Wolf highlights that predictive biomarkers need to be identified to guide combination treatment.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
Related videos
2:03
TKIs to treat EGFRm-positive NSCLC
Marina Garassino
1:16
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex
1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
1:03
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex
2:06
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
